77 related articles for article (PubMed ID: 22459331)
1. Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Breccia M; Efficace F; Alimena G
Leuk Res; 2012 Jul; 36(7):804-5. PubMed ID: 22459331
[No Abstract] [Full Text] [Related]
2. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
3. The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors.
Copeland AC; Foster MC; Muluneh B; Xenakis JG; Ivanova A; Frankfurt O; Clayton M; Black A; Rapchak B; Wehbie RS
Leuk Lymphoma; 2019 Jul; 60(7):1842-1844. PubMed ID: 30773105
[No Abstract] [Full Text] [Related]
4. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D
J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869
[TBL] [Abstract][Full Text] [Related]
6. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
[TBL] [Abstract][Full Text] [Related]
7. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
8. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.
Haque R; Shi J; Chung J; Xu X; Avila C; Campbell C; Ahmed SA; Chen L; Schottinger JE
J Am Pharm Assoc (2003); 2017; 57(3):303-310.e2. PubMed ID: 28259737
[TBL] [Abstract][Full Text] [Related]
9. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
10. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies.
Hewison A; Atkin K; McCaughan D; Roman E; Smith A; Smith G; Howell D
Eur J Oncol Nurs; 2020 Apr; 45():101730. PubMed ID: 32169687
[TBL] [Abstract][Full Text] [Related]
11. Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
Cayssials E; Tartarin F; Guilhot J; Sorel N; Chomel JC; Leleu X; Guilhot F
Leuk Lymphoma; 2018 Mar; 59(3):766-769. PubMed ID: 28792265
[No Abstract] [Full Text] [Related]
12. T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: a report of 14 cases.
Gong Z; Xie W; Wang W; Chen Z; Xu J; Yuan J; Zhou Y; Wang D; Medeiros LJ; Hu S
Int J Lab Hematol; 2017 Apr; 39(2):e45-e50. PubMed ID: 27863007
[No Abstract] [Full Text] [Related]
13. What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?
Lewis M; Copland M; Soverini S; Sadovnik I; Bedel A; Prost S; Italiano A; Mahon FX
Hematol Oncol; 2017 Dec; 35(4):420-423. PubMed ID: 27435333
[TBL] [Abstract][Full Text] [Related]
14. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
16. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
Takahashi N
Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
[No Abstract] [Full Text] [Related]
17. Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.
Claudiani S; Apperley JF; Deplano S; Khorashad J; Foroni L; Palanicawandar R; Perry R; Milojkovic D
Am J Hematol; 2016 Nov; 91(11):E480-E481. PubMed ID: 27467708
[No Abstract] [Full Text] [Related]
18. [Chronic myelogenous leukemia: diagnosis and treatment].
Demeter J; Poros A; Bödör C; Horváth L; Masszi T
Orv Hetil; 2016 Sep; 157(37):1459-68. PubMed ID: 27615196
[TBL] [Abstract][Full Text] [Related]
19. VEGF in chronic myeloid leukemia treated with interferon and imatinib.
Aguayo A
Leuk Res; 2014 Jun; 38(6):660-1. PubMed ID: 24726782
[No Abstract] [Full Text] [Related]
20. Bcr-Abl tyrosine kinase inhibitors: a patent review.
Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
